For over four decades, HIV has been one of the deadliest pandemics in human history, claiming the lives of more than 44 million people since 1981. Until recently, a diagnosis meant a near-certain death sentence, particularly in underserved regions where access to treatment remains limited. Sin embargo, el panorama ha cambiado dramáticamente.
Global progress has been staggering. Deaths from AIDS-related illnesses have fallen by 70% since their peak, and approximately 30 million people now live with HIV while being sustained on antiretroviral therapy (ART). Estos medicamentos han transformado el virus de una condición fatal a una enfermedad crónica manejable. Even more groundbreaking, long-acting injectable medications are now available that provide up to six months of HIV prevention with a single dose, and the prospect of a functional vaccine is becoming increasingly realistic.
Por primera vez, erradicar el VIH no es sólo una posibilidad teórica, sino un objetivo tangible a nuestro alcance.
Sin embargo, en esta coyuntura crítica, el respaldo financiero y político que impulsó este éxito está amenazado. Funding for global health programs—the same programs that have saved countless lives—are facing drastic cuts both internationally and domestically. Esta reducción de la inversión es particularmente peligrosa porque existen las herramientas para derrotar al VIH; el único obstáculo que queda es mantener la voluntad de desplegarlos de manera efectiva.
No se trata sólo de una cuestión de estadísticas abstractas. Reduced funding will directly translate into lost lives, increased infections, and a resurgence of a disease that was once considered unstoppable. The coming months will see increased scrutiny of how HIV programs operate, from the role of pharmaceutical companies to the lived experiences of those affected.
La pregunta que tenemos ante nosotros ya no es si podemos acabar con el VIH, sino si lo haremos. La respuesta depende del compromiso sostenido, no del abandono.
This reporting is sponsored by Gilead Sciences, with full editorial control retained by Vox. This disclosure is important because pharmaceutical partnerships play a vital role in HIV research and treatment access, and transparency is essential to maintaining public trust.
